PAS
DNA icon

Park Avenue Securities’s Ginkgo Bioworks DNA Stock Holding History

Park Avenue Securities’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-339
Closed -$16K – 1371
2024
Q1 		$16K Buy
+339
New +$17.5K ﹤0.01% 1358

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Park Avenue Securities's DNA Position: Q2 2024 in Review

Park Avenue Securities sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 339 shares — an estimated $16K sold.

Park Avenue Securities first reported a position in DNA in Q1 2024 and held it in 1 quarter. The position peaked at $16K in Q1 2024. 312 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Park Avenue Securities reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Park Avenue Securities sold 339 Ginkgo Bioworks shares in Q2 2024, an estimated $16K.
  • Park Avenue Securities first reported a position in Ginkgo Bioworks in Q1 2024 and held it in 1 quarter.
  • Park Avenue Securities's Ginkgo Bioworks position peaked at $16K in Q1 2024.
  • 312 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Park Avenue Securities's 13F filing for Q2 2024, filed 9 Jul 2024.